The recent development of a class of drugs called“correctors”, which repair the structure and functionof mutant CFTR, has greatly enhanced the life expectancy of CF patients.These correctors target the most common disease causing CFTR mutantF508del and are exemplified by the FDA-approved VX-809. This evidence concerns the gene CFTR and cystic fibrosis.